Ambulero: Funding, Investors & Team (Sep 2026)
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
Ambulero has raised $5.5M across 1 funding round on record, the most recent a Seed of $5.5M announced in Jan 2021.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Ambulero Company Profile and Key Stats
Latest funding round on record: Jan 2021.
Ambulero Funding Rounds
Ambulero Founders and Leadership Team
Contact details for the Ambulero team: 1 of 1 has an email address on file.
Start 14-day free trial →Ambulero Funding Compared to Other Biotechnology Startups
Ambulero's latest round of $5.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ambulero in Biotechnology and Miami
Companies Similar to Ambulero
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Ambulero Funding FAQs
What does Ambulero do?
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
How much funding has Ambulero raised?
Ambulero has raised $5.5M across 1 round on record. The most recent is a Seed of $5.5M announced in Jan 2021.
When did Ambulero last raise funding?
Ambulero's most recent funding round on record is a Seed of $5.5M, announced in Jan 2021.
Who is the CEO of Ambulero?
Robert Buchanan is listed as CEO at Ambulero.
Where is Ambulero headquartered?
Ambulero is based in Miami, Florida, United States.
How many employees does Ambulero have?
Ambulero is in the 1-10 employee band.
How does Ambulero's funding compare to other Biotechnology startups?
Ambulero's latest round of $5.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Ambulero Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ambulero is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.